Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Open-label, Proof-of-concept Study With Safety Run-in to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Adult Subjects With Basal Cell Carcinoma

Next Previous
Trial Profile

A Phase 2, Multicenter, Open-label, Proof-of-concept Study With Safety Run-in to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Adult Subjects With Basal Cell Carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxotemitide (Primary)
  • Indications Basal cell cancer
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Sponsors Verrica Pharmaceuticals

Most Recent Events

  • 30 Sep 2026 According to a Verrica Pharmaceuticals media release, the data from the trial will be presented at the Fall Clinical Dermatology Conference (October 8-11, Wynn Las Vegas, Las Vegas, NV) and at the 2026 PeDRA Annual Conference (October 15-17, Alexandria, VA).
  • 10 Sep 2026 According to a Verrica Pharmaceuticals media release, the data from the trial will be presented at two upcoming dermatology conferences in September 2026: the 27th Annual Las Vegas Dermatology Seminar (September 17-20, Bellagio, Las Vegas, NV) and Maui Derm NP+PA Fall 2026 (September 16-19, The Greenbrier, White Sulphur Springs, WV).
  • 06 May 2026 Results presented in a Verrica Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top